GLP1R and metabolic dysfunction-associated steatohepatitis: Furthermore, tirzepatide, a novel GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist used for treating T2DM and promoting weight loss, showed promising effects in patients with MASH and stage 2–3 fibrosis in a recent phase 2 trial [76].